Evidence map›Paper›PMID 35880178›Full record

ReviewFrontiers in immunology2022

Peroxisome Proliferator-Activated Receptors Regulate Hepatic Immunity and Assist in the Treatment of Primary Biliary Cholangitis.

Chang Wang, Ying Shi, Xiaomei Wang, Heming Ma, Quan Liu, Yanhang Gao, Junqi Niu

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Effects of kiwi fruit (Frontiers in nutrition · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Chang WangDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Ying ShiDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Xiaomei WangDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Heming MaDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Quan LiuInstitute of Translational Medicine, The First Hospital of Jilin University, Changchun, China.
Yanhang GaoDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
Junqi NiuDepartment of Hepatology, The First Hospital of Jilin University, Changchun, China.
First Hospital of Jilin University · CNJilin University · CNHenan Provincial People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibrates, which are agonists of peroxisome proliferator-activated receptor alpha, have received increasing attention in the treatment of primary biliary cholangitis. Reduced alkaline phosphatase levels and improved clinical outcomes were observed in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid (UDCA) monotherapy4 when treated with bezafibrate or fenofibrate combined with UDCA. In contrast to obeticholic acid, which exacerbates pruritus in patients, fibrates have been shown to relieve pruritus. Clinical trial outcomes show potential for the treatment of primary biliary cholangitis by targeting peroxisome proliferator-activated receptors. It is currently agreed that primary biliary cholangitis is an autoimmune-mediated cholestatic liver disease, and peroxisome proliferator-activated receptor is a nuclear receptor that regulates the functions of multiple immune cells, thus playing an important role in regulating innate and adaptive immunity. Therefore, this review focuses on the immune disorder of primary biliary cholangitis and summarizes the regulation of hepatic immunity when peroxisome proliferator-activated receptors are targeted for treating primary biliary cholangitis.

Indexed as

Cholagogues and CholereticsLiver Cirrhosis, BiliaryFibric AcidsHumansPPAR alphaPruritusUrsodeoxycholic AcidCholagogues and CholereticsFibric AcidsPPAR alphaUrsodeoxycholic Acidcholestatic liver diseasefibratehepatic immunityperoxisome proliferator-activated receptorprimary biliary cholangitis

Identifiers

PMID35880178
PMCPMC9307989
OpenAlexW4284886918

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.